Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. Taverna
Combination of Irak4 (Ca-4948) and BTK (Vecabrutinib) Inhibitors Show Superior Efficacy in Preclinical Models of Abc DLBCL Tumors Containing Myd88 -L265p Mutations
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Kym-001, a First-In-Class Oral Irak4 Protein Degrader, Induces Tumor Regression in Xenograft Models of Myd88-Mutant Abc DLBCL Alone and in Combination With BTK Inhibition
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Schnitzler Syndrome Associated With MYD88 L265P Mutation
JAAD Case Reports
Dermatology
L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
PLoS ONE
Multidisciplinary
Tumors With AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy With AKT Inhibitors
Molecular Cancer Therapeutics
Cancer Research
Oncology
Pancreatic Cancer: Circulating Tumor Cells and Primary Tumors Show Heterogeneous KRAS Mutations
Scientific Reports
Multidisciplinary
Cell Line‐based Assessment of BTK Inhibitors
British Journal of Pharmacology
Pharmacology
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
Mediterranean Journal of Hematology and Infectious Diseases
Infectious Diseases
Hematology
Preclinical Efficacy of Belinostat in Combination With Zidovudine in Adult T-Cell Leukemia-Lymphoma
Retrovirology
Virology
Infectious Diseases
MEF2B Mutations Are Functionally Significant in DLBCL
Cancer Discovery
Oncology
